Drug Profile
Binodenoson - Pfizer
Alternative Names: Binodisine; CorVue; MRE 0470; MRE-0740Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Aderis Pharmaceuticals (CEASED)
- Developer King Pharmaceuticals Research and Development
- Class Purine nucleosides; Small molecules; Vasodilators
- Mechanism of Action Adenosine A2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
- 22 Oct 2009 King Pharmaceuticals receives complete response letter from the FDA for adjunctive binodenoson in Cardiovascular disorders diagnosis
- 19 Dec 2008 Preregistration for Cardiovascular disorders (aid in diagnostic imaging adjunct to SPECT) in USA (IV)